Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a breakthrough medication category that has dramatically altered the treatment paradigm for type 2 diabetes and related medical conditions. These advanced pharmaceuticals operate by blocking glucose reabsorption within the kidneys, allowing the body to expel excess sugar via urine, thereby achieving natural blood glucose reduction....